Pharmaceutical Drug Development and BABE

The cost of returned medicines is estimated to be between $5-10 billion per year in the US alone. However, pharmaceutical companies are struggling to streamline the data flow and verification of returned saleable goods.

The science of medicine has allowed us to make incredible advances in diagnosing and treating diseases. But the complexity of human biology is staggering. Every person is unique and in many ways, so are diseases. Yet the digital revolution in healthcare provides new ways to both collect high-quality data from each patient and connect it to data from large pools of other patients for analysis. This enables us to arrive at a deeper understanding of how to treat an individual. Only then can we see what distinguishes each of us as individuals, and translate that into personalized and thus improved care for every person. Real-world evidence, molecular information generated from next-generation sequencing, data from wearable devices and mobile apps and novel clinical trials are transforming the future of care.

There has been growing interest in Pichia for use in the production of biopharmaceuticals including: SARS CoV2 spike protein and RBD, antibodies and other proteins for medicinal purposes.

Patient Support Programs (PSPs) have changed dramatically over the past decade; they have become global activities, and grown significantly in scale and complexity. While PSPs are also an increasingly valuable resource for pharmacovigilance due to the extensive patient safety data they generate, they have suffered from the traditional lack of standardized mechanisms for recording, reconciling and managing this data, resulting in resource heavy processes, and a lost opportunity for deeper product understanding for Pharma. Fortunately, new technologies are helping to tackle this challenge.